Co-D Therapeutics
Co-D Therapeutics: A preclinical biopharmaceutical firm innovating safe, first-in-class cancer nanomedicines.
Founded
2012Co-D Therapeutics: A preclinical biopharmaceutical firm innovating safe, first-in-class cancer nanomedicines.
Co-D Therapeutics, Inc. is a preclinical-stage biopharmaceutical company founded in Madison, Wisconsin. The company's core mission is to develop innovative, first-in-class combination nanomedicines with high safety profiles to treat cancer. Utilizing advanced polymeric micelle technology, Co-D aims to enhance drug delivery to solid tumors. Their primary product, Triolimus, is a nanomedicine that combines paclitaxel, rapamycin, and 17-AAG for effective combination cancer therapy. Co-D Therapeutics is focused on establishing strategic partnerships to advance their nanomedicine programs.
Notable affiliated individuals include key researchers and scientists specializing in oncology and nanotechnology. Co-D Therapeutics has garnered attention from investors interested in groundbreaking cancer treatments. Among its key achievements is the development of Triolimus, which represents a significant advancement in combination cancer therapy. The company's innovative approach has the potential to significantly impact cancer treatment by improving drug delivery and efficacy, ultimately aiming to enhance patient outcomes.
Companies similar to Co-D Therapeutics include Cello Therapeutics, NanoValent Pharmaceuticals, OncoNano Medicine and NanoMedTrix.
Co-D Therapeutics was founded in 2012.
Co-D Therapeutics' headquarters is located in Madison, WI, US.
As of Sep 1, 2018, Co-D Therapeutics has disclosed funding of $145k (USD). Undisclosed round amounts are excluded.
Co-D Therapeutics has 7 employees as of Feb 5, 2024.
NanoMedTrix
